Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Icahn Turns Up The Heat On Amylin, Urges Board To Sell

Apr 04 2012

Related Content

Amylin, Lilly End Exenatide Tie-Up, Marking End To Litigation

Nov 08 2011

Weeks After <em>Bydureon</em> Launch, Amylin Looks Like A Takeout Target

Mar 29 2012

With Bydureon’s U.S. Approval, Amylin Extends Exenatide Franchise

Jan 27 2012

With Lilly Out, Amylin’s Future Is Tied To <em>Bydureon</em>

Nov 30 2011

Forest Holds Off Icahn, But Battle Likely Looms

Aug 18 2011

Related Companies

Bristol Myers Squibb Company

Bristol Myers Squibb Company

AstraZeneca PLC

Novartis AG

Roche Holding AG

Takeda Pharmaceutical Co. Ltd.

GSK plc

Pfizer Inc.

Merck & Co., Inc.

Novo Nordisk A/S

Eli Lilly and Company

Boehringer Ingelheim GmbH

Biogen, Inc.

Sanofi Genzyme

Forest Laboratories, Inc.

Additional Topics

Deals BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window